CBFB and acute myeloid leukemia: Although the use of high-dose cytarabine has improved the outcome of core binding factor (CBF) AML, we still lack efficient strategies to selectively inactivate the RUNX1–RUNX1 partner transcriptional co-repressor 1 (RUNX1T1, a.k.a. CBFA2T1 or ETO) or CBFB–MYH11 driver fusions.